Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma: A Multicenter, Randomized, Open-Label, Non-Inferiority Phase III Clinical Study

Immunotherapy combined with chemoradiotherapy has become standard care for locally advanced nasopharyngeal carcinoma, yet radiotherapy-induced lymphopenia may impair the efficacy of concurrent PD-1 blockade. Existing evidence supports synergistic anti-tumor activity between the anti-EGFR antibody nimotuzumab and toripalimab. This multicenter, open-label, non-inferiority Phase III trial randomizes eligible stage III-IVA LA-NPC patients 1:1 to two arms. The experimental group receives an "immune sandwich" regimen: TPC induction plus nimotuzumab and toripalimab, concurrent radiotherapy with weekly nimotuzumab only, followed by toripalimab maintenance. The control arm adopts full-course toripalimab throughout induction, concurrent radiotherapy and adjuvant phases. The primary endpoint is 3-year event-free survival, with secondary endpoints covering overall survival, local/distant control rates, objective response rate and treatment-related toxicities. A total of 566 subjects will be enrolled to verify whether the simplified sandwich strategy delivers non-inferior survival with better safety profiles.

Start Date20 Jul 2026

Sponsor / Collaborator

Sun Yat-Sen University

[+1]

NCT07707973

/ Not yet recruitingPhase 2IIT

A Single-arm, Phase II Study of Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma

This is a prospective, single-arm study. The study population consists of adult patients with a confirmed diagnosis of EGFR-positive high-grade glioma who have radiographic residual tumor following surgical resection. Participants will receive nimotuzumab in combination with the standard Stupp regimen after glioma surgery.

Start Date03 Jul 2026

Sponsor / Collaborator-

ChiCTR2600126570

/ Not yet recruitingPhase 2IIT

Prospective, Single-Arm, Phase Ⅱ Clinical Study of Nimotuzumab Combined with Chemotherapy as Neoadjuvant Therapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma

Start Date01 Jul 2026

Sponsor / Collaborator-

100 Clinical Results associated with Nimotuzumab

100 Translational Medicine associated with Nimotuzumab

100 Patents (Medical) associated with Nimotuzumab

408

Literatures (Medical) associated with Nimotuzumab

13 Mar 2026·JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Induction chemotherapy plus PD-1 blockade and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: a propensity-matched retrospective study

Article

Author: Mao, Yichen ; He, Yiyue ; He, Xia ; Wu, Lirong ; Mu, Zhongde ; Zong, Dan

Abstract:

Objective:

Despite standard induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT), locoregionally advanced nasopharyngeal carcinoma (LANPC) continues to relapse and metastasize at high rates. Recent advances suggest that integrating immunotherapy and target agents may improve outcomes. This study aimed to evaluate the short-term efficacy and safety of combining PD-1 inhibitor and nimotuzumab with induction chemotherapy in LANPC patients.

Methods:

We retrospectively analyzed 197 patients with LANPC treated at our institution between January 2022 and December 2023. Patients received either induction chemotherapy (IC) alone or IC plus PD-1 inhibitor and nimotuzumab (ICIT), followed by CCRT. Propensity score matching yielded 90 IC and 45 ICIT patients for analysis. Efficacy, adverse events, and survival outcomes were evaluated after induction and full course.

Results:

The median follow-up duration was 22.8 months. Induction best overall response was higher with ICIT than with IC alone (95.6% vs. 80.0%, P = .03), driven by a marked reduction in stable disease. Subgroup analysis showed pronounced benefit in males, patients with advanced N stage, and those with high epidermal growth factor receptor expression. The ICIT group showed a trend toward improved early tumor shrinkage, with no locoregional failures observed. Hematologic toxicities were similar between groups, while the ICIT group experienced higher rates of grade 3 mucositis and hepatic toxicity.

Conclusions:

Adding PD-1 inhibitor plus nimotuzumab to induction chemotherapy improved early tumor shrinkage while maintaining an acceptable safety profile. These encouraging early data reinforce the need for ongoing prospective trials to confirm long-term benefit and to refine patient selection.

02 Mar 2026·MOLECULAR PHARMACEUTICS

Paired Agent Imaging to Evaluate the Improvement of Affinity-Matured Nimotuzumab K4 and K5 Variants as EGFR-Detecting Optical Imaging Agents

Article

Author: Tundidor, Yaima ; Jett, Kimberly A. ; Geyer, C. Ronald ; Barreto, Kris ; Toledo, Darien ; Bernhard, Wendy ; Rojas, Gertrudis

Molecular imaging is a useful tool for the in vivo validation of antibody therapeutics. It shows the accumulation properties of antibodies in tumors and organs that cannot be predicted by using in vitro assays. Two issues with characterizing antibodies using in vivo imaging are: (i) the fluorescent signal from the antibody is sensitive to its depth in the tissue, and (ii) there are large biological variabilities observed in in vivo imaging studies. Paired agent imaging measures the fluorescence of a test antibody and a control antibody in the same animal, allowing the fluorescence of the test antibody to be normalized to that of the control antibody. We used paired agent imaging to compare the in vivo imaging properties of two affinity-matured variants of the anti-EGFR antibody nimotuzumab (K4 and K5) to the parental antibody. To perform paired agent imaging, we labeled the test antibodies (K4 and K5) with IRDye800CW and the control antibody (nimotuzumab) labeled with IRDye680RD, and coinjected them into mice bearing EGFR-positive xenografts. Near-infrared fluorescent imaging was used to quantitate the relative amount of each antibody present in tumors and organs. Paired agent imaging allowed us to detect differences in in vivo fluorescence between K4, K5, and nimotuzumab, where K5 had the highest accumulation in the tumor, followed by K4 and nimotuzumab.

01 Mar 2026·NEUROSCIENCE

The efficacy of combination therapy versus monotherapy in patients with glioblastoma with abnormal epidermal growth factor receptor (EGFR) genes, a systematic review and network meta-analysis

Review

Author: Du, Yuejiao ; Che, Luhao ; Xu, Songbai ; Fan, Liding ; Yan, Xiaokai ; Wu, Hao ; Yu, Bo ; Li, Yanhua ; Feng, Junjie ; Zhang, Yi

The primary objective of this study is to evaluate the efficacy of various pharmaceuticals (combination therapy versus monotherapy) in patients with glioblastoma (GB) with abnormal epidermal growth factor receptor (EGFR) genes. Clinical trials to investigate the therapeutic effects of different therapy was searched by PubMed, Embase, Web of Science, Cochrane Library, and Google Scholar. The Cochrane Risk of Bias Assessment Tool and data analysis software will be applied. Data collection spanned from the earliest available date up to April 2025. Eight studies involving a total of 2,137 individuals were included, with 657 of these receiving combination therapies and 1,480 receiving monotherapies. The analysis revealed that combination therapies generally demonstrated superior efficacy compared to the single ones, while monotherapies exhibited greater potency than temozolomide (TMZ). In terms of median progression-free survival (PFS), the combinations of Afatinib plus TMZ (SUCRA: 62.28%), rindopepimut (CDX-110) plus TMZ (SUCRA: 62.27%), and depatuxizumab mafodotin (Depatux M) plus TMZ (SUCRA: 54.4%) ranked among the top tier. For median overall survival (OS), the combinations of CDX-110 plus TMZ (SUCRA: 68.8%), Depatux M plus TMZ (SUCRA: 68.3%), and Nimotuzumab plus TMZ (SUCRA: 52.5%) were positioned in the upper echelon. In terms of prolonging both median PFS and median OS in GB, CDX-110 plus TMZ and Depatux M plus TMZ have shown slightly better than comparable therapies. However, further clinical trials are needed to confirm the effectiveness of other drugs in this respect.

News (Medical) associated with Nimotuzumab

14 Sep 2022

·www.globenewswire.com

MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma

LA JOLLA, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office for a new patent which covers MN-166 (ibudilast) for the treatment of glioblastoma. This new patent is expected to expire no earlier than February 2039. The allowed claims cover a method of treating a patient diagnosed with glioblastoma or recurrent glioblastoma, wherein the patient expresses unmethylated MGMT, using MN-166 (ibudilast) in combination with one or more other therapeutic agents including temozolomide (TMZ), carmustine, bevacizumab, procarbazine, hydroxyurea, irinotecan, lomustine, nimotuzumab, sirolimus, mipsagargin, cabozantinib, onartuzumab, patupilone (epothilone B), and recombinant oncolytic poliovirus (PVS-RIPO). The allowed claims cover a wide range of doses of MN-166 (ibudilast) as well as the other therapeutic agents. The allowed claims also cover different types of glioblastoma including classical glioblastoma, proneural glioblastoma, mesenchymal glioblastoma, and neural glioblastoma. Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc. commented, “We are very pleased to receive the issue notification for this new patent as it offers additional coverage compared to our other two patents covering glioblastoma. We have an ongoing clinical trial of MN-166 in combination with temozolomide for the treatment of recurrent glioblastoma at the Dana-Farber Cancer Institute, Harvard Medical School. Results of our glioblastoma animal model study showed that median survival was longer in the group that received combination treatment with MN-166 plus temozolomide compared to the group that received the standard treatment of temozolomide alone, and this data was presented at the American Society of Clinical Oncology (ASCO) annual meeting. Encouragingly, the FDA granted orphan-drug designation to MN-166 as adjunctive therapy to temozolomide for the treatment of glioblastoma based on this data.” About Glioblastoma According to the American Association of Neurological Surgeons, glioblastoma is an aggressive brain cancer that often results in death during the first 15 months after diagnosis. Glioblastoma develops from glial cells (astrocytes and oligodendrocytes), grows rapidly, and commonly spreads into nearby brain tissue. Glioblastoma is classified as Grade IV, the highest grade, in the World Health Organization (WHO) brain tumor grading system. The American Brain Tumor Association reports that glioblastoma represents about 15% of all primary brain tumors and approximately 10,000 cases of glioblastoma are diagnosed each year in the U.S. Despite decades of advancements in neuroimaging, neurosurgery, chemotherapy and radiation therapy, only modest improvements have been achieved and the prognosis has not improved for individuals diagnosed with glioblastoma. Median survival is about 11-15 months for adults with more aggressive glioblastoma (IDH-wildtype) who receive standard treatment of surgery, temozolomide, and radiation therapy. About MN-166 (ibudilast) MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative cervical myelopathy); and is also in development for glioblastoma, CIPN (chemotherapy-induced peripheral neuropathy), and substance use disorder. In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS). About MediciNova MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in glioblastoma and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants. Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2021 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements. INVESTOR CONTACT:Geoff O'BrienVice PresidentMediciNova, Inc.info@medicinova.com

Radiation TherapySmall molecular drugASCOCollaborateIPO

25 Sep 2019

·www.biospace.com

Biocon Biologics Expands its R&D Footprint Through Acquisition

60,000 sq. ft World-class Integrated R&D Facility at TICEL Bio Park to House 250 scientists 60,000 sq. ft World-class Integrated R&D Facility at TICEL Bio Park to House 250 scientists Bengaluru, Karnataka, India: September 24, 2019: Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia’s premier biopharmaceuticals company, today announced that its subsidiary, Biocon Biologics , has acquired R&D capital assets for a 60,000 sq. ft state-of-the-art ‘bench to pilot scale’ Biologics research facility at TICEL Bio Park in Chennai, India. Biocon Biologics has acquired these assets from Pfizer Healthcare India Ltd. Dr Christiane Hamacher, CEO, Biocon Biologics, said: “The high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide. This investment will allow us to fast-forward development of our biosimilars from lab to pilot scale. R&D is at the core of what we do and I believe this facility will enable us to pursue breakthrough innovation in pursuit of providing affordable access to high quality biosimilars and inclusive healthcare solutions aimed at transforming patient lives globally.” The facility will house an early stage research and innovation center including a pilot scale R&D Unit, well-equipped with cell line development, drug substance process development from bench scale to 400 litre scale bioreactors, drug product formulation laboratories and analytical R&D laboratories. The facility is expected to be operational in a few months post qualification and will house over 250 scientists who will have access to state of the art R&D labs equipped with over 500 high- end process and analytical instrumentation. The new facility provides Biocon Biologics a significant time advantage in comparison to setting up a greenfield R&D project and will accelerate the global development of our biosimilars portfolio. Currently, Biocon Biologics has a 200,000 sq. ft state of the art Research & Development Centre at Biocon Park, Bengaluru, India. The Company has a product pipeline of 28 molecules, including 11 with Mylan, few with Sandoz and rest on its own. The financial details of the deal are confidential. TICEL Bio Park at Chennai, Tamil Nadu, India, is a hub for the biotech R&D industry in major domains such as medical biotechnology, nutraceuticals, agricultural biotechnology and bioinformatics and provides world class infrastructure support. About Biocon Biologics Biocon Biologics is a subsidiary of Biocon Ltd, an innovation led global biopharmaceuticals company. Biocon Biologics is engaged in developing high quality, affordable biosimilars that can expand access to a cutting-edge class of therapies to patients globally. It is uniquely positioned as the fully integrated ‘pure play’ biosimilars organization in the world and aspires to transform patient lives through innovative and inclusive healthcare solutions. The Company has a large portfolio of biosimilars under global clinical development with three of these commercialized in the developed markets of EU, U.S. and Japan. It has obtained approvals and commercialized a range of biosimilars, including monoclonal antibodies for cancer, Pegfilgrastim, rh-Insulin and Insulin Glargine on its own or through partners in key global markets. Biocon Biologics believes that strong partnerships offer enormous opportunities to co-create the future of healthcare, building a patient ecosystem beyond the product, which can transform millions of lives. About Biocon Ltd: Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is a fully-integrated, innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. The Company has developed and commercialized a range of Biosimilars (Monoclonal Antibodies, Pegfilgrastim, rh- Insulin and Insulin Glargine), Novel Biologics and differentiated Small Molecules in India and key emerging markets. It has a large portfolio of biosimilars and promising novel assets in immunotherapy under global development. Some of its key formulations brands are INSUGEN® (rh-insulin), Basalog One® (prefilled Glargine pen), CANMAb™ (Trastuzumab), KRABEVA® (Bevacizumab), BIOMAb-EGFR® (Nimotuzumab) and ALZUMAb™ (Itolizumab). Follow-us on Twitter: @bioconlimited FOR MORE INFORMATION MEDIA RELATIONS Seema Ahuja Sr. VP & Global Head, Corporate Communications (+91 80 2808 2222 ( +91 99723 17792 * seema.ahuja@biocon.com INVESTOR RELATIONS Saurabh Paliwal Head, Investor Relations ( +91 80 6775 2040 ( +91 95383 80801 * investor.relations@biocon.com DISCLAIMER : This press release may include statements of future expectations and other forward-looking statements based on management’s current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release.

ImmunotherapyDrug ApprovalAcquisition

25 Apr 2014

·www.daiichisankyo.com

Daiichi Sankyo Announces Discontinuation of Phase 3 Clinical Trial in Japan of Nimotuzumab (DE-766) in Lung Cancer

PDF (61KB)PDF For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Noriaki Ishida, Corporate Officer, Vice President, Corporate Communications Department Telephone: +81-3-6225-1126 http://www.daiichisankyo.com/ TOKYO, Japan (April 25, 2014) - Daiichi Sankyo Company, Limited announced today the discontinuation of the phase 3 clinical trial conducted in Japan for nimotuzumab (DE-766) in Lung Cancer. The phase 3 clinical trial was a multicenter, randomized, double-blind, placebo-controlled study investigating nimotuzumab for first-line therapy in patients with unresectable and locally advanced squamous cell lung cancer. Patients received either nimotuzumab in combination with concurrent chemoradiotherapy or a placebo in combination with concurrent chemoradiotherapy. The study was discontinued based on the recent recommendation of the Independent Data Monitoring Committee which observed safety issues in certain patients who received a combination of cisplatin, vinorelbine, radiotherapy, and nimotuzumab. About Unresectable and Locally Advanced Squamous Cell Lung Cancer In Japan, lung cancer is the first leading cause of cancer death with about 70,000 deaths in 2011.i Non-small cell lung cancer (adenocarcinoma, squamous cell carcinoma, and large cell carcinoma) occupies more than 80 percent of lung cancer. Concurrent chemoradiotherapy for a radical cure is currently used as the standard treatment for patients with stage III locally advanced non-small cell lung cancer, in which radical surgery is not possible but radiotherapy is.ii Of these cases, between 30 and 40 percent are squamous cell carcinoma and EGFR is known to be overexpressed.iii About Nimotuzumab and EGFR Nimotuzumab is an intravenously administered recombinant humanized monoclonal antibody directed against human Epidermal Growth Factor Receptor (EGFR) and is produced by CIMAB S.A. (Cuba). nimotuzumab blocks the binding of Epidermal Growth Factor (EGF) to its receptor interfering with the cell signaling pathway. Nimotuzumab has been approved for head and neck cancer, glioma, and esophageal cancer in several countries and used in 29 completed and 26 on-going trials worldwide without any major safety concern so far. EGFR is known to be overexpressed in a wide variety of human tumors.iv Overexpression of EGFR in tumors correlates with increased metastasis, decreased survival, and a poor prognosis. It is known that EGFR is activated by exposure to radiation. In 2006, Daiichi Sankyo introduced nimotuzumab from CIMAB S.A. and CIMYM BioSciences Inc. (Canada) and has the rights to develop and commercialize in Japan. Reference i) Vital Statistics of Japan (Ministry of Health, Labour and Welfare); 2011. ii) Lung Cancer Clinical Practice Guidelines (Japan Lung Cancer Society); 2012. iii) Ito T, Ishii G, Nagai K, et al. Low podoplanin expression of tumor cells predicts poor prognosis in pathological stage IB squamous cell carcinoma of the lung, tissue microarray analysis of 136 patients using 24 antibodies. Lung Cancer 2009; 63(3):418–424. iv) Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232.

Phase 3Drug Approval

100 Deals associated with Nimotuzumab

External Link

KEGG	Wiki	ATC	Drug Bank
-	Nimotuzumab	L01XC	DB06192

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pancreatic Cancer	China	Biotech Pharmaceutical Co., Ltd.	07 Jun 2023
Squamous Cell Carcinoma of Head and Neck	Indonesia	Innogene Kalbiotech Pte Ltd.	19 Oct 2022
Nasopharyngeal Carcinoma	China	Biotech Pharmaceuticals Pty Ltd	07 Jan 2008
Glioma	Ukraine	Oncoscience AG	10 Oct 2007
Head and Neck Neoplasms	India	Biocon Biopharmaceuticals Pvt Ltd.	11 Sep 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastroesophageal junction adenocarcinoma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	01 Aug 2024
Gastrooesophageal junction cancer	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	01 Aug 2024
stomach adenocarcinoma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	01 Aug 2024
Metastatic Colorectal Carcinoma	Phase 3	-	Biotech Pharmaceutical Co., Ltd.	01 Apr 2024
Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	01 Nov 2021
Diffuse Intrinsic Pontine Glioma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	03 Apr 2021
Cervical Squamous Cell Carcinoma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	10 May 2016
Esophageal Squamous Cell Carcinoma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	13 Nov 2015
Metastatic Esophageal Squamous Cell Carcinoma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	01 Nov 2015
Uterine Cervical Cancer	Phase 3	Algeria	-	28 Oct 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2026	Not Applicable	Locally Advanced Head and Neck Squamous Cell Carcinoma	75	Concurrent chemoradiotherapy (CCRT) (Intermediate high-risk (e.g., pT3-4, N2-3))	rxrveyylkk(fvybsjrrir) = xtgxflzaab yhqkuxugta (vmlwauskwl ) View more	Positive	29 May 2026
				nimotuzumab plus CCRT (Extranodal extension/positive margins)	rxrveyylkk(fvybsjrrir) = kxlnhylvdq yhqkuxugta (vmlwauskwl ) View more
NCT06879691 (ASCO2026)	Phase 3	Head and Neck Neoplasms	194	nimotuzumab + analgesics + CCRT	mgjowdinob(celcfkpygi) = oizztuhoor jmmofqnkxh (zamisbssvq ) View more	Positive	29 May 2026
				analgesics + CCRT	mgjowdinob(celcfkpygi) = qtiudfsbue jmmofqnkxh (zamisbssvq ) View more
ASCO2026	Not Applicable	Metastatic Esophageal Squamous Cell Carcinoma First line EGFR gene amplification	497	Nimotuzumab + Paclitaxel + Cisplatin	nrbfjnswje(sktrltemnj) = idtksjtkez vnqfachvoj (dslluqrsgf ) View more	Positive	29 May 2026
				Placebo + Paclitaxel + Cisplatin	nrbfjnswje(sktrltemnj) = ptdapzaume vnqfachvoj (dslluqrsgf ) View more
ChiCTR2200063875 (ASCO2026)	Phase 2	Oesophageal squamous cell carcinoma recurrent	42	Nimotuzumab + CCRT	juohgopewa(lgzkwlipps) = sarzgnvlnc jwfszrgrje (gifrsfehqy ) View more	Positive	29 May 2026
NCT06048913 (ASCO2026)	Phase 2	Esophageal Squamous Cell Carcinoma	56	Nimotuzumab plus S-1 and concurrent radiotherapy	htqpyucayw(kivfwzvtcx) = dvgoyxuhax vvrszrcjhj (vpyaftpaae, 55.5 - 80.1) View more	Positive	29 May 2026
ASCO2026	Not Applicable	Pancreatic Cancer Neoadjuvant EGFR expression	100	AG regimen alone	xfqvszksas(sradrrchgi) = ejiarilamq uwxabhstry (xmnnzqotac ) View more	Positive	29 May 2026
				AG regimen + nimotuzumab	xfqvszksas(sradrrchgi) = oewzlxspmp uwxabhstry (xmnnzqotac ) View more
AACR2026	Not Applicable	Liver metastases CXCR4 \| LITAF	23	Nimotuzumab plus AG	scumbajqfz(pstpfqcvyq) = zqgeokdajd dkeviexzfv (yrsdtvfiad ) View more	Positive	19 Apr 2026
NCT04223024 (Pubmed \| Nat Commun)	Phase 2	Advanced Nasopharyngeal Carcinoma	246	Nimotuzumab plus Concurrent Chemoradiotherapy	amunpqdrqi(jkfansamjq) = jretwreohf nhcjybnroy (asvadbzkvx, 74.3 - 86.1)	Negative	31 Mar 2026
				Concurrent Chemoradiotherapy	amunpqdrqi(jkfansamjq) = yxskcfrmjw nhcjybnroy (asvadbzkvx, 74.2 - 85.7)
NCT06414577 (ESMO_ASIA2025)	Phase 2	Refractory Nasopharyngeal Carcinoma	36	Liposomal irinotecan 70 mg/m2+nimotuzumab 400 mg	tgkygmnuyh(ozarllfiik) = ppzriuvwci tuelhuhdpp (bzwlavrili ) View more	Positive	06 Dec 2025
ESMO_ASIA2025	Phase 3	Advanced Nasopharyngeal Carcinoma	352	nimotuzumab during induction chemotherapy	ftgilrmnpx(dkzzisuflf) = ehiysjsooh fwmlhohdaw (xjgsojjsyi ) View more	Positive	06 Dec 2025
				nimotuzumab during CCRT	ftgilrmnpx(dkzzisuflf) = iftyguxhdl fwmlhohdaw (xjgsojjsyi ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis